Trial
NCT03597035
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University Hospitals Cleveland Medical Center
Collaborators
Relypsa, Inc.
Condition
Type2 Diabetes
Intervention
Spironolactone
Why stopped
The study could not enroll patients owing to the inclusion exclusion criteria
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-16